

PUTRI, ZEHAN

9/37 STANTON RD, MOSMAN. 2088

Birthdate:19/10/1979 **Sex:**F **Medicare Number:**2640161598
Your Reference:00000336 **Lab Reference:**22-20342650-LIP-0
Laboratory:Laverty Pathology
Addressee:DR DAVID COSGRIFF **Referred by:**DR DAVID COSGRIFF

Name of Test:LIPID STUDIES (LIP-0)
Requested:05/09/2022 **Collected:**05/09/2022 **Reported:**05/09/2022 20:44

LIPID STUDIES

Specimen Type: Serum

Reference intervals are included for reference only, and interpretation / treatment goals should be guided by patient-specific cardiovascular risk assessment (see Australian Cardiovascular Risk Charts. Alternatively, the web-site www.cvdcheck.org.au can be accessed in order to complete a risk assessment for individual patients.)

Haemolysis	Nil
Icterus	Nil
Lipaemia	Nil

Fasting status	Random
Total Cholesterol	4.3 mmol/L (3.9-5.2)
Triglycerides	2.4 mmol/L (0.5-1.7)
HDL Cholesterol	1.0 mmol/L (1.0-2.0)
LDL Cholesterol	2.2 mmol/L (1.5-3.4)
Non-HDL Cholesterol	3.3 mmol/L (< 3.4)
Cholesterol/HDL-C Ratio	4.3 (< 4.5)

NVDPA TARGET LIPID RANGES (MMOL/L) FOR PATIENTS AT HIGH / MODERATE RISK OF CARDIOVASCULAR DISEASE:

TOTAL CHOLESTEROL	<4.0	
----- -----		
TRIGS (FASTING)	<2.0	
----- -----		
HDL-C	>= 1.0	
----- -----		
LDL-C	<2.0	
----- -----		
NON HDL-C	<2.5	

This pattern may be seen in non-fasting specimens, pregnancy, with oestrogen or bile-acid sequestrant therapy and increased alcohol intake.

LDL-C exceeds target for higher risk patients and may be excessive in some individuals.

Requested Tests : TFT, GLU*, CRP, MBA, LIP, FE, FBE, DVI*